Summary
Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy. In order to combine the rapid hypocalcemic effects of calcitonin with the more delayed effect of a bisphosphonate, we administered etidronate, 7.5 mg/kg/day intravenously and salmon calcitonin, 100 IU subcutaneously, every 12 hours for 3 days in 9 patients with hypercalcemia associated with malignancy. The mean serum calcium concentration fell from 3.33±0.1 mmol/liter (mean±SEM) to 2.88±0.1 mmol/liter within 24 hours (P<0.001). All patients had a fall in the serum calcium concentration of >0.5 mmol/liter and it returned to normal in 7 of the 9 patients. We conclude that the combination of salmon calcitonin with etidronate more effectively lowers the serum calcium concentration in patients with hypercalcemia of malignancy then the use of either agent alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercalcemia. Q J Med 50:473–481
Mundy GR, Martin JT (1982) The hypercalcemia of malignancy: pathogenesis and management. Metabolism 31:1247–1277
Ralston SH, Gardner MD, Dryburgh FJ (1985) Comparison of aminohydroxypropylidine diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcemia. Lancet 2:207–210
Lazor MZ, Rosenberg LE (1964) Mechanism of adrenal-steroid reversal of hypercalcemia in multiple myeloma. N Engl J Med 270:749–755
Thalassinos NC, Joplin GF (1970) Failure of corticosteroid therapy to correct the hypercalcemia of malignant disease. Lancet 2:537–538
Fulmer DH, Dimich AB, Rothschild EO, Myers WPL (1972) Treatment of hypercalcemia. Arch Intern Med 129:923–930
Percival RC, Yates AJP, Gray RES (1984) Role of glucocorticoids in management of hypercalcemia. Br Med J 289:287
Wisneski LA (1990) Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46:S26-S30
Silva OL, Becker KL (1973) Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 132:337–339
Thiebaud D, Burckhardt P, Jaeger PH, Azria M (1987) Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia. Am J Med 82:745–750
Hosking DJ, Gilson D (1984) Comparison of the renal and skeletal action of calcitonin in the treatment of severe hypercalcemia of malignancy. Q J Med 111:359–368
Binstock ML, Mundy GR (1980) Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Int Med 93:269–272
Warrell RP, Israel R, Frisone M, Synder T, Gaynor JJ, Brockman RS Gallium nitrate for acute treatment of cancer related hypercalcemia: a randomized, double blind comparison to calcitonin. Ann Int Med 108:669–674
Fleisch H (1987) Bisphosphonates. History and experimental basis. Bone 8:S23-S28
Ryzen E, Martodam RR, Trotell M, Benon A, Paterson A, Shepard K, Hicks R (1985) Intravenous etidronate in the management of malignant hypercalcemia. Arch Int Med 145:449–452
Jacobs TP, Gordon AC, Silverberg SJ, Shane E, Reich L, Clemens TL, Gundberg CM (1987) Neoplastic hypercalcemia: physiologic response to intravenous etidronate sodium. Am J Med 82:42–50
Hasling C, Charles P, Moskilde L (1987) Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med 82:51–54
Jung A (1982) Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 72:221–226
Kanis JA, Urwin GH, Gray RES, Beneton MNC, McClowskey EV, Hamdy NAT, Murray SA (1987) Effect of intravenous etidronate disodium in skeletal and calcium metabolism. Am J Med 82:55–70
Singer FR, Ritch PS, Lad TE, Ringenberg QS, Shiller JH, Recker RR, Ryzen E (1991) Treatment of hypercalcemia of malignancy with intravenous etidronate: a controlled multicentered study. Arch Intern Med 151:471–476
Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT (1989) Comparison of three intravenous bisphosphonates in cancer associated hypercalcemia. Lancet 2:1180–1182
Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FAO, Martin TJ (1986) Abundant calcitonin receptors in isolated rat osteoclasts. J Clin Invest 78:355–360
Singer FR, Melvin KEW, Mills BG (1976) Acute effects of calcitonin on osteoclasts in man. Clin Endocrinol 5(suppl):333s-340s
Ralston SH, Alzaid AA, Gardner MD, Boyle IT (1986) Treatment of cancer associated hypercalcemia with combined aminohydroxy-propylidene diphosphonate and calcitonin. Br Med J 292:1549–1550
Thiebaud MD, Jacquet AF, Burckhardt P (1990) Fast and effective treatment for malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino α1-hydroxypropylidene-1-bisphosphonate. Arch Intern Med 150:2124–2128
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fatemi, S., Singer, F.R. & Rude, R.K. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 50, 107–109 (1992). https://doi.org/10.1007/BF00298784
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00298784